Variation of HIV-1 mutation spectra among cell types

Journal of Virology

Volumn 87, Issue 9, 2013, Pages 5296-5299

  Holtz, Colleen M ^a,b   Mansky, Louis M ^a,b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE; CELL PROTEIN; GUANINE; MESSENGER RNA; PROTEIN APOBEC3; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; APOBEC3 GENE; ARTICLE; CELL FUNCTION; CELL TYPE; CONTROLLED STUDY; EMBRYO; GENE; GENE EXPRESSION; GENE FREQUENCY; GENE SEQUENCE; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; MUTATION RATE; MUTATIONAL ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEQUENCE ANALYSIS; VIRUS MUTATION;

BASE SEQUENCE; CELL LINE; GENETIC VARIATION; HIV INFECTIONS; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; MUTATION RATE; SPECIES SPECIFICITY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84876327353     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.03576-12     Document Type: Article

References (23)

1. Hankins CA, Dybul MR. 2013. The promise of pre-exposure prophylaxis with antiretroviral drugs to prevent HIV transmission: a review. Curr. Opin. HIV AIDS 8:50-58.
2. Mansky LM. 1998. Retrovirus mutation rates and their role in genetic variation. J. Gen. Virol. 79:1337-1345.
3. Dapp MJ, Patterson SE, Mansky LM. 2013. Back to the future: revisiting HIV-1 lethal mutagenesis. Trends Microbiol. 21:56-62.
4. Sheehy AM, Gaddis NC, Choi JD, Malim MH. 2002. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418:646-650.
5. Zheng YH, Irwin D, Kurosu T, Tokunaga K, Sata T, Peterlin BM. 2004. Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication. J. Virol. 78:6073-6076.
6. Harris RS, Bishop KN, Sheehy AM, Craig HM, Petersen-Mahrt SK, Watt IN, Neuberger MS, Malim MH. 2003. DNA deamination mediates innate immunity to retroviral infection. Cell 113:803-809.
7. Yu Q, Konig R, Pillai S, Chiles K, Kearney M, Palmer S, Richman D, Coffin JM, Landau NR. 2004. Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome. Nat. Struct. Mol. Biol. 11:435-442.
8. Sadler HA, Stenglein MD, Harris RS, Mansky LM. 2010. APOBEC3G contributes to HIV-1 variation through sublethal mutagenesis. J. Virol. 84:7396-7404.
9. Hultquist JF, Lengyel JA, Refsland EW, LaRue RS, Lackey L, Brown WL, Harris RS. 2011. Human and rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H demonstrate a conserved capacity to restrict Vif-deficient HIV-1. J. Virol. 85:11220-11234.
10. Mansky LM, Temin HM. 1995. Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J. Virol. 69:5087-5094.
11. O'Neil PK, Sun G, Yu H, Ron Y, Dougherty JP, Preston BD. 2002. Mutational analysis of HIV-1 long terminal repeats to explore the relative contribution of reverse transcriptase and RNA polymerase II to viral mutagenesis. J. Biol. Chem. 277:38053-38061.
12. Zhang J. 2004. Host RNA polymerase II makes minimal contributions to retroviral frame-shift mutations. J. Gen. Virol. 85:2389-2395.
13. Bebenek K, Roberts JD, Kunkel TA. 1992. The effects of dNTP pool imbalances on frameshift fidelity during DNA replication. J. Biol. Chem. 267:3589-3596.
14. Julias JG, Pathak VK. 1998. Deoxyribonucleoside triphosphate pool imbalances in vivo are associated with an increased retroviral mutation rate. J. Virol. 72:7941-7949.
15. Diamond TL, Roshal M, Jamburuthugoda VK, Reynolds HM, Merriam AR, Lee KY, Balakrishnan M, Bambara RA, Planelles V, Dewhurst S, Kim B. 2004. Macrophage tropism of HIV-1 depends on efficient cellular dNTP utilization by reverse transcriptase. J. Biol. Chem. 279:51545-51553.
16. Mansky LM. 1996. Forward mutation rate of human immunodeficiency virus type 1 in a T lymphoid cell line. AIDS Res. Hum. Retroviruses 12: 307-314.
17. Dorweiler IJ, Ruone SJ, Wang H, Burry RW, Mansky LM. 2006. Role of the human T-cell leukemia virus type 1 PTAP motif in Gag targeting and particle release. J. Virol. 80:3634-3643.
18. Doria M, Neri F, Gallo A, Farace MG, Michienzi A. 2009. Editing of HIV-1 RNA by the double-stranded RNA deaminase ADAR1 stimulates viral infection. Nucleic Acids Res. 37:5848-5858.
19. Doria M, Tomaselli S, Neri F, Ciafre SA, Farace MG, Michienzi A, Gallo A. 2011. ADAR2 editing enzyme is a novel human immunodeficiency virus-1 proviral factor. J. Gen. Virol. 92:1228-1232.
20. Phuphuakrat A, Kraiwong R, Boonarkart C, Lauhakirti D, Lee TH, Auewarakul P. 2008. Double-stranded RNA adenosine deaminases enhance expression of human immunodeficiency virus type 1 proteins. J. Virol. 82:10864-10872.
21. Refsland EW, Stenglein MD, Shindo K, Albin JS, Brown WL, Harris RS. 2010. Quantitative profiling of the full APOBEC3 mRNA repertoire in lymphocytes and tissues: implications for HIV-1 restriction. Nucleic Acids Res. 38:4274-4284.
22. Bourara K, Liegler TJ, Grant RM. 2007. Target cell APOBEC3C can induce limited G-to-A mutation in HIV-1. PLoS Pathog. 3:1477-1485.
23. Koning FA, Goujon C, Bauby H, Malim MH. 2011. Target cell-mediated editing of HIV-1 cDNA by APOBEC3 proteins in human macrophages. J. Virol. 85:13448-13452.